Your manuscript on CtIP regulation by APC/C-Cdh1 has now been seen by three expert referees, whose comments are copied below. As you will see, all referees acknowledge the overall interest and general technical quality of this work, but they also point out a number of limitations that would require revision before publication will be warranted. Should you be able to satisfactorily address these points as detailed below, we shall be happy to consider a revised manuscript further for publication in The EMBO Journal.
One main issue concerns the effects of Cdh1 loss on genomic instability, and the probably overstated role of CtIP as the key substrate responsible for this. Here, I feel it would be important to be more circumspect in the presentation and discussion of this aspect, and also to more carefully acknowledge previously reported results on Cdh1 genome stability roles. At the same time, given the main focus on the target CtIP, I do not feel that further experiments such as those requested in referee 2's point 1 and 6 would be necessary; regarding this referee's 2nd point, checking possible G2 arrest defects and their impact on CtIP stability would be helpful, while experimentally addressing (rather than just discussing) apparent differences between Cdh1-/-DT40 cells and the three human cell lines used here would in my view not be essential.
The other key issue is the somewhat counterintuitive outcome of CtIP stabilization, to whose explanation only rather tentative models are presented. Although I understand that directly monitoring resection in mammalian cells is likely not trivial, I do feel that some additional followup experimentation to validate the proposed model would be important here, possibly by following referee 3's suggestion to look at Rad51 loading/recruitment in Cdh1-depleted or CtIP-K467A-Please note that it is our policy to allow only a single round of major revision, making it important to comprehensively and diligently answer to all points at this stage. This letter of response will also form part of the Review Process File, and will therefore be available online to the community in case of publication. We generally allow three months as standard revision time, and competing manuscripts published during this period will not negatively impact on our final assessment of your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension.
Should you have any questions regarding this decision or your revision, please do not hesitate to contact me for further discussions. Thank you again for the opportunity to consider this work for publication, and I look forward to your revision! _____ REFEREE REPORTS:
Referee #1:
In this article, the authors describe the targeting of CtIP by the APC. CtIP is an important regulator of DNA end resection. It has been previously shown in both humans and yeast that Cdk phosphorylation regulates CtIP such that NHEJ is favored in G1, when Cdk is low, and that CtIP promotes resection, and therefore HR, when Cdk levels are high in G2. Here, the authors show that CtIP is also an APC-Cdh1 target, which is logically consistent with its previously known regulation: APC-Cdh1 would drive down CtIP levels in G1, and allow its activity in G2.
The first part of the manuscript shows that reducing Cdh1 levels causes genomic instability. Almost everything in the first figure has been published previously, and while this can be found in the text, it is probably not as obviously stated as it should be. When the authors note that cdh1 KD causes increases in p53, for example, they should cite the previous papers showing the same response. This should be done throughout. In the second, related figure, the authors show that repair is altered in cdh1. This is more novel, and more likely related to their other observations.
Figures 3-5 go about showing that CtIP is a Cdh1 substrate. These figures are very nice and the work is quite solid. Finally, they make a stabilized allele and examine phenotypes. This is where things yield unexpected results. The simple result would be that the stable allele increases resection and promotes HR and SSA, analogously to how the loss of CtIP reduces HR and SSA. In an effort to explain these results, the authors come up with a somewhat complicated, but nevertheless possible, model. They do a few experiments to examine this model, but don't go as far as one might and never look at resection directly.
As a whole, I think this is a nice story and worthy of publication. The experiments as they are presented are well controlled and reasonably complete. I could list a half dozen experiments that they could do to take this further, but I think that the analysis has been taken to a sufficient depth here. Other reviewers may disagree on this point.
As a final note, the authors provide one logical flaw which is rampant in this sort of analysis. They start by showing that an enzyme that hits myriad substrates causes some general defect (e.g. cdh1 loss causes genomic instability). They next show that a single substrate has a biological role consistent with this effect, and go on to write the paper as if this is THE substrate responsible for said effect. This is normally simply an attempt to ascribe a larger phenotype than actually exists for the loss of targeting for a single substrate. The authors should change the wording accordingly to note in the abstract/intro that while CtIP targeting could contribute to the effects seen in figure 1, many many other substrates likely contribute as well.
Referee #2:
In this report, authors showed that APC/CCdh1 is important for the maintenance of genome stability. When Cdh1 was inactivated by shRNAs, checkpoint was activated, H2AX was accumulated and bridging chromosomes in anaphase were observed. Meanwhile, inactivation of Cdh1 led to enhanced sensitivity to DNA damaging agents. By mass spectrometry analysis of changes in protein abundance upon mitotic exit, CtIP was identified as a potential substrate of APC/CCdh1. Authors further demonstrated that CtIP interacts with Cdh1 through the KEN box and showed that CtIP is a substrate of APC/CCdh1 for ubiquitination and degradation both during mitotic exit and upon DNA damage. In addition, the CtIP and Cdh1 interaction is important for both HR and SSA but dispensable for NHEJ. These studies revealed an important function of APC/CCdh1 in the maintenance of genome stability and identified CtIP, a repair protein as one substrate of APC/CCdh1 for maintaining genome stability. These findings are interesting but there are a number of important issues on the assays and interpretations of the results that have to be addressed.
1. Authors showed that inactivation of Cdh1 causes H2AX foci formation, but the effect at the chromosomal levels were not analyzed. Metaphase chromosome spreads should be carried out to show chromosomal breakage and other chromosomal abnormality when Cdh1 function is impaired. Authors showed that IR-induced Rad51 foci were reduced in Cdh1 depleted cells and based on this, they claimed that HR may be defective. A direct test using HR, SSA and NHEJ repair substrates should be performed to show which DSB repair pathways are defective in Cdh1 shRNAs expressing cells. It is important to compare these results with that from the CtIP-KEN mutant in HR, SSA and NHEJ to support the idea that Cdh1 repair function is largely through modulating CtIP abundance.
2. It was shown that the growth curves of chicken DT40 Cdh1-/-cells were indistinguishable from that of wild-type cells (EMBO J 20: 6499) . But in this study, figure 1B showed a G2/M arrest when Cdh1 shRNAs are expressing, while no cell cycle changes were seen in Suppl. Fig. S4A and S4B. What causes these differences? In addition, DT40 Cdh1-/-cells fail to maintain DNA damage-induced G2 arrest, but such effect was not directly tested in this study. Cell cycle profiles of wild-type and Cdh1 shRNA deficient cells, both asynchronized and synchronized, before and after IR and Dox treatment need to be shown along with the stability of CtIP. This is important for indicating whether Cdh1 deficiency in human cells would impair damage-induced G2 arrest and whether such defect would influence CtIP stability.
3. There is a concern to use nocodazole to arrest cells at prometaphase and immediately test CtIP stability after releasing, since nocodazole arrest activates spindle checkpoint. In addition, the migration of CtIP in SDS-PAGE gel is much slower after nocodazole treatment than untreated samples (Fig.4C 4G) , and it was not addressed what caused slower migration of CtIP upon nocodazole treatment and whether this would influence CtIP stability.
4. It needs to show associations of both endogenous Cdh1 and CtIP and test whether such interactions are regulated during cell cycle and upon DNA damage. On the same line, it needs to show whether endogenous CtIP is ubiquitinated and whether such ubiquitination is regulated during cell cycle and upon DNA damage.
5. Unlike CtIP-T847A, the CtIP-K467A mutant defective in Cdh1 interaction was able to promote RPA2 phosphorylation as wild-type CtIP after DNA damage. Based on this, the authors believed that the CtIP-Cdh1 interaction is not strictly required for the initiation of DNA end resection (early-phase end resection), but may affect the extent of resection (late-phase end resection). However, it is not clear whether late-phase end resection is more extensive or restricted in the CtIP-K467A mutant. Experiments need to be carried out to show whether the end resection is more or less extensive after initial end resection in the CtIP-K467A mutant compared to the wild-type CtIP. Considering prolonged retention of the CtIP-K467A mutant at the sites of DNA breaks, the mutant may have more extensive late-phase end resection, and if this is the case, it needs to explain how resulted more extensive end resection affects HR and SSA.
6. The manuscript does not show the biological consequences of the CtIP-K467A mutant. It is important to show whether the CtIP-K467A mutant is sensitive to DNA damaging agents, accumulates H2AX and chromosomal aberrations, and exhibits bridging chromosomes in anaphase. The results should be compared with that from Cdh1 deficient cells and be discussed in the "Discussion section" to address whether CtIP is a critical substrate of APC/CCdh1 for the maintenance of genome stability. 7. The model illustrated in figure 8 needs to be explained better. It will be helpful to discuss in more details why CtIP removal is required for proper HR in the delayed response to DSBs.
Minor points: 1. Inactivation of Cdh1 causes DNA damage. In Fig. 2C , siCdh1#1 no treatment sample (lane 4) does not show KAP1-S824 phosphorylation. This is not consistent with other damage responses such as p53 stabilization and H2AX phosphorylation when Cdh1 is inactivated (Fig.1A ).
Referee #3:
In this manuscript Lafranchi and colleagues present a compelling account of experiments that uncover a novel function for the anaphase promoting complex/cyclosome in regulating DNA double-strand break repair pathway execution in a cell-cycle and DNA damage-dependent manner. Understanding the molecular mechanisms that modulate DNA repair, at the level of protein turnover and the fine-tuning of DNA repair factors to modulate repair pathway choice or execution is of great importance, as misregulation at this level results in the genomic instability that can be causative of human disease, and is known to be a major driver of cancer.
Previous research has hinted at roles for the APC-CDH1 sub-complex in regulating genome stability beyond its better-characterized functions during mitosis, yet the key substrates and molecular mechanism of its action in this regard are largely undefined. In this work the authors investigate this issue, first describing a role for CDH1 in cellular responses to DNA double-strand breaks (DSBs), and then using proteomics to identify new factors that are down regulated by APC/C-CDH1 that may help explain this function. Significantly, CtIP, a master regulator of DNA end resection is identified as a novel substrate of the APC/C-CDH1 complex, observations that the authors can then explain through CDH1-targetting of CtIP via a conserved KEN box. Supportive of these findings, a comprehensive biochemical and mutational analysis of this interaction is demonstrated, forming the basis from which CtIP KEN-box function is then probed in multiple cell-lines, using chemical inhibitors and rescue experiments. CtIP regulates HR by promoting DNA resection, however a very interesting observation the authors make is that although the CtIP-KEN box mutation results in HR defects, these do not arise due a defect in resection initiation. In fact the K467A mutant is contrasted with a T847A CDK phosphorylation mutant which has a defined role in resection activation, highlighting that CtIP degradation is likely more important at the latter stages of repair where CtIP displacement would be required for downstream recombination (could this be at level of Rad51 loading/recruitment as was found for CDH1-depleted cells?-this could be examined or commented upon). Thus, while these results help explain the previously described regulation of CtIP protein levels throughout the cell-cycle, they also indicate CtIP-degradation is an important for its removal in the later stages of a DNA damage response to enable downstream repair execution.
APC-CDH1 is likely to target multiple substrates that may directly and/or indirectly affect genomic instability and DNA repair, thus the impact CDH1-depletion has on DNA damage responses may be quite complex. However the described data make a strong case that the regulation of CtIP stability in a cell-cycle and DNA damage responsive manner is indeed an important function of this pathway. I find the presented data to be of high quality, and the experiments to be very well controlled.
Moreover, the authors' use of multiple complementary approaches to address the central function of APC/CDH1-CtIP regulation leads to convincing overall conclusions. Based on this, I think this work will be of wide appeal to scientists in the fields of DNA repair/genome stability research and can strongly support its publication in Embo Journal, subject to a few minor corrections/amendments listed below: ï In general, Figure 7F could be better described in the figure legend and the fact that the WB is currently labeled siCdh1 was quite confusing. I presume this is a mistake and it should be labeled siCtIP instead. ï Page 21, 4 line from bottom: CtIP 'retrains' ExoI activity; Do the authors mean 'restrains'?
1st Revision -authors' response 07 September 2014
Point-by-point rebuttal:
Referee #1: Response: In order to study DNA-end resection in more detail, we have now isolated stable U2OS clones inducibly expressing an siRNA-resistant CtIP allele that cannot interact with Cdh1 (K467A KEN-box mutant). In line with several previous studies in human cells, we made use of RPA2 phosphorylation levels (RPA2-pS4/S8) as a direct readout for DNA-end resection. As speculated on in the original manuscript, we now show that replacing endogenous CtIP with the CtIP-K467A mutant results in increased RPA2 phosphorylation in response to ionizing radiation both in asynchronously growing cells (new Fig 7D and E7B) and, more pronounced, in G2-enriched cells (new Fig 8F) . Response: We agree with the reviewer that the APC/C-Cdh1 has many substrates, and that the DNA damage response phenotypes we report in Cdh1-depleted cells are most likely emerging from deregulated expression of various Cdh1 substrates. In our study, we are focusing on CtIP, a key DNA-end resection factor, as a novel Cdh1 substrate, which highlights a thus far unexplored role of Cdh1 in the regulation of DSB repair. In the revised manuscript we have changed our wording at several places in line with this notion. The new data also illustrates that CtIP regulation through Cdh1 does not explain all phenotypes associated with Cdh1 inactivation. Specifically, expression of the CtIP-K467A mutant does not cause radiation hypersensitivity (new Fig. E8A ), whereas Cdh1 inactivation did (Fig 2B) . Also the increased sensitivity of Cdh1-depleted cells for doxorubicin ( Fig.  2A and new Fig. E8C ) was not observed in cells expressing the K467A-CtIP mutant (new Fig.  E8B ). Instead, blocking the interaction of CtIP with Cdh1 does lead to increased sensitivity to PARP inhibition, to a similar extent as observed in Cdh1-depleted cells (new Fig. 8E ).
Reviewer
Reviewer point 1: Authors showed that inactivation of Cdh1 causes γH2AX foci formation, but the effect at the chromosomal levels were not analyzed. Metaphase chromosome spreads should be carried out to show chromosomal breakage and other chromosomal abnormality when Cdh1 function is impaired. Authors showed that IR-induced Rad51 foci were reduced in Cdh1 depleted cells and based on this, they claimed that HR may be defective. A direct test using HR, SSA and NHEJ repair substrates should be performed to show which DSB repair pathways are defective in Cdh1 shRNAs expressing cells. It is important to compare these results with that from the CtIP-KEN mutant in HR, SSA and NHEJ to support the idea that Cdh1 repair function is largely through modulating CtIP abundance.
Response: According to our data and previously published data, Cdh1-depleted cells and Cdh1-deficient cells are genomically instable. We agree with the referee that metaphase chromosome spreading would be a suitable method to qualitatively assess whether Cdh1 inactivation gives rise to chromosomal aberrations (in absence or presence of exogenous genotoxic stress). In fact, it was recently reported in budding yeast that lack of Cdh1 increased the rate of gross chromosomal rearrangements (Ayuda-Duran et al., NAR 2014). Moreover, Cdh1-null cells were shown to display high rates of chromosomal translocations (Garcia-Higuera et al., Nat. Cell Biol., 2008 and Engelbert et al., Oncogene, 2008) . These observations can be explained by multiple defects, including premature S-phase entry with unscheduled origin firing. We show in Figure 1 that shRNA-mediated Cdh1 depletion leads to a strong increase in aberrant anaphases. This phenotype was observed at 5 days after infecting MCF7 cells with pLL-Cdh1 lentiviral shRNA. In this context, we feel that carrying out other laborious experiments as metaphase chromosome spreading is beyond the scope of this manuscript and instead decided to focus our efforts more on the characterization of CtIP as a novel Cdh1 substrate during the revision. To which extent Cdh1-depleted cells are defective in homology-directed repair of DSBs is of course an interesting and relevant issue, especially in the context of our manuscript. Two previously published genome-wide HR screens by the groups of Elledge (Adamson, Nature Cell Biology, 2012, PMID-22344029) and Buchholz (Słabicki et al, 2010, PLoS Biology, PMID-20613862) did not identify Cdh1 as being required for HR (see figure below) . However, in the Adamson study, Cdh1 depletion was stated to have altered proliferation. Nevertheless, we have performed DR-GFP assays with siCdh1 and observed a modest decrease in HR. However, we have noted a decrease in S/G2 cells upon Cdh1-depletion in these assays, which will probably bias HR repair reporter assays and preclude firm statements on a potential DNA repair defect after Cdh1 depletion. We therefore decided not to include these data in the manuscript, and feel that in order to reliably report on the effects of Cdh1 depletion on HR repair, a more thorough investigation is required, which to our opinion, is beyond the scope of this manuscript. to be required for HR (RAD51, BRCA1 and BRCA2) as well as genes that were shown to prevent HR (TP53BP1 and NUP153) were indicated. In red, the HR scores of Cdh1 depleted cells are indicated. J 20: 6499) . But in this study, figure 1B showed a G2/M arrest when Cdh1 shRNAs are expressing, while no cell cycle changes were seen in Suppl. Fig. S4A 
Legend to Figure:

Reviewer point 2. It was shown that the growth curves of chicken DT40 Cdh1-/-cells were indistinguishable from that of wild-type cells (EMBO
and S4B. What causes these differences? In addition, DT40 Cdh1-/-cells fail to maintain DNA damage-induced G2 arrest, but such effect was not directly tested in this study. Cell cycle profiles of wild-type and Cdh1 shRNA deficient cells, both asynchronized and synchronized, before and after IR and Dox treatment need to be shown along with the stability of CtIP. This is important for indicating whether Cdh1 deficiency in human cells would impair damage-induced G2 arrest and whether such defect would influence CtIP stability.
Response: We indeed observed altered cell cycle distributions after Cdh1 depletion, with increased numbers of cells at the G 2 /M transition. These observations are in line with data from GarciaHiguera in Cdh1-/-MEFs (2008). These effects are much more pronounced after shRNA-compared to siRNA-mediated depletion of Cdh1. The important different between these experiments is that shCdh1-depleted cells are analyzed 5 days after lentiviral infection but siCdh1 transfection only lasted for 2 days. Therefore, in our experiments based on shRNA-mediated downregulation of Cdh1, DNA damage will have more time to accumulate and consequently results in more pronounced cell cycle changes. The second point raised by the reviewer concerns the cell cycle checkpoint defect reported in Cdh1 -/-chicken DT40 cells. An important difference between the cell lines that we used and the DT40 cells is the p53 status. Whereas DT40 cells are p53-defective (Takao et al, Oncogene, 1999) , all cell lines that we used with the exception of HeLa cells have functional p53 (MCF7, RPE-1 and U2OS). Both Cdh1 and CtIP have been linked to cell cycle checkpoint behavior previously. We have now analyzed this function in more detail in cells depleted of Cdh1 or CtIP, and in cells expressing CtIP mutant alleles. These data are now included in Figures E7C and E7D and show that Cdh1 depletion does not result in a checkpoint defect in our experimental conditions. In contrast, CtIP depletion did cause defective G 2 /M checkpoint maintenance, which was rescued by expression of CtIP-wt. Notably, expression of the CtIP-K467A mutant also rescued the checkpoint defect induced by CtIP siRNA, indicating that the interaction between Cdh1 and CtIP is not required for checkpoint initiation or maintenance.
Reviewer point 3: There is a concern to use nocodazole to arrest cells at prometaphase and immediately test CtIP stability after releasing, since nocodazole arrest activates spindle checkpoint. In addition, the migration of CtIP in SDS-PAGE gel is much slower after nocodazole treatment than untreated samples (Fig.4C 4G), and it was not addressed what caused slower migration of CtIP upon nocodazole treatment and whether this would influence CtIP stability.
Response: We have also noted that CtIP migrates much slower in nocodazole-arrested cells compared to untreated cells. As it has been repeatedly reported by quantitative phosphoproteomic approaches that nocodazole treatment results in increased protein phosphorylation levels (e.g. Nagano et al. Proteomics, 2009), we assessed whether this is also the case for CtIP. Indeed, we find that the CtIP mobility shift in response to nocodazole treatment can be mainly attributed to phosphorylation (see new Fig. E4B ). It will of course be interesting to determine the role of CtIP hyperphosphorylation during mitosis. A possible scenario is that one or several kinases that are activated in mitosis phosphorylate CtIP at various sites to inactivate DNA-end resection at this stage of the cell cycle. Such a scenario would fit with recent evidence from the Durocher lab that DSBs in mitosis are neither processed nor repaired and that this phenomenon is, at least partially, mediated by inhibitory phosphorylation of 53BP1 (Orthwein et al, Science, 2014) . In addition, and as pointed out by the referee, it is possible that such modification of CtIP initially protects CtIP from degradation, and that only after (rapid) post-mitotic dephosphorylation has occurred, the APC/CCdh1 interacts with CtIP and promotes its degradation. We think that this issue clearly warrants further investigations that are beyond the scope of this manuscript.
In the context of our experiments, the ability of nocodazole treatment to activate the spindle assembly checkpoint was used to synchronize cells in prometaphase. We have now experimentally addressed the concern of the reviewer that nocodazole treatment might influence the stability of CtIP. Firstly, we used an alternative method to synchronize cells in prometaphase. We used the reversible Eg5 inhibitor S-trityl-L-cysteine (STLC, as also used in e.g. Janssen et al, Science 2011 and Santaguida, J Cell Biol 2010). Eg5 inhibition also activates the SAC, but does so without affecting microtubule dynamics. Importantly, we find similar degradation kinetics of CtIP upon mitotic exit. Secondly, we used the reversible Cdk1 inhibitor RO-3306 to enrich cells prior to mitotic entry, as was previously described (Vassilev, Cell Cycle 2006) . Again, we find that CtIP levels are down-regulated upon mitotic exit. These data are included in Figure 4D and E4A.
Reviewer point 4: It needs to show associations of both endogenous Cdh1 and CtIP and test whether such interactions are regulated during cell cycle and upon DNA damage. On the same line, it needs to show whether endogenous CtIP is ubiquitinated and whether such ubiquitination is regulated during cell cycle and upon DNA damage.
Response: These are certainly both valid points. We have tried in reciprocal experiments to coimmunoprecipate endogenous Cdh1 together with CtIP from high amounts of whole cell lyates using several available anti-Cdh1 and anti-CtIP antibodies, respectively. Unfortunately, without much success. This could be due to several reasons: First, there is the issue of epitope masking. Second, and as pointed out by this reviewer, the Cdh1-CtIP interaction is cell-cycle and/or DNAdamage regulated and most likely occurs only after exit from mitosis or in G2 cells after DNA damage. Third, enzyme-substrate interactions as those between E3 ligases (or kinases) and their target proteins are generally considered to be very transient and, thus, very difficult to detect using standard co-IP experiments. With regards to the second point, we have now included new data in which ubiquitination of endogenous CtIP is studied (new Figure 6C) . Specifically, we have synchronized cells in G 2 phase, and assessed ubiquitin conjugation to endogenous CtIP after irradiation. In line with our previous data, we observed poly-ubiquitination of endogenous CtIP after irradiation, which was reduced in cells treated with the APC/C inhibitor proTAME. Response: We agree with the reviewer that this is an important point, which was also raised by reviewer 1. We have now included more extensive data on DNA-end resection. Specifically, we have analyzed the amount of phosphorylated RPA2, both in total cell lysates and chromatinenriched samples in response to ionizing radiation in G 2 cells. Specifically, we have done these experiments in selected monoclonal cell lines of the inducible U2OS cell lines, which express the GFP-CtIP variants to similar levels. We observed a clear increase in the amount of phospho-RPA2 in cells expressing CtIP-K467A, compared to cells expressing CtIP-wt. As a control in these experiments, we included the CtIP-T847A mutant, which was previously shown to be defective in promoting DNA-end resection, and clearly see lower amounts of resection. These new data are now shown in Figures 7D and 8F . 
Response:
We have now investigated several phenotypes of the CtIP-K467A mutant. To this end, we have again used our monoclonal cell lines, expressing similar levels of GFP-CtIP-wt or GFPCtIP-K467A. As mentioned above (point 2), we have performed DNA damage checkpoint assays, and now show that the GFP-CtIP-K467A mutant does not interfere with checkpoint initiation or checkpoint maintenance. In addition, we have tested the sensitivity of the GFP-CtIP-K467A-expressing cells to DNA-damaging agents. Whereas the GFP-CtIP-K467A-expressing cells do not display increased radiosensitivity (new Figure E8A) , and no increased sensitivity to doxorubicin (new Figure E8B) , we observed that these cells have increased sensitivity to PARP inhibition (new Figure 8E ), as seen in Cdh1-depleted cells ( Figure 8E ). Combined, these data indicate that CtIP is an important Cdh1 target in the context of HR, but that aberrant CtIP regulation in the absence of Cdh1 does not explain all phenotypes associated with loss of Cdh1.
Reviewer point 7:
The model illustrated in figure 8 needs to be explained better. It will be helpful to discuss in more details why CtIP removal is required for proper HR in the delayed response to DSBs.
Response:
In the revised manuscript we have updated and simplified our model according to our new data (new Figure 9) . Moreover, we took care of more extensively explaining the model. (Fig.1A) .
Response: In Figure 2C , the untreated siCdh1#1 sample is compared with irradiated samples, and within this comparison, we do not see KAP1-S824 phosphorylation. This might indicate that the amounts of DNA damage inflicted by transient Cdh1 depletion are relatively minor when compared to the levels of DNA damage shortly after irradiation. Moreover, as explained in point 1, these cells were treated 2 days with an siRNA targeting Cdh1, whereas cells shown in Fig.1A were shRNAtreated for 5 days. 
We have now included data on DNA-end resection and Rad51 recruitment in Figure 8F . Using RPA2 phosphorylation to monitor end resection, we now show that monoclonal cell lines expressing GFP-CtIP-K467A show excessive end resection in response to DNA break formation in G 2 cells, when compared to GFP-CtIP-wt-expressing cells. Importantly, when chromatin fractions of these cells were analyzed we again observed an increase in phosphorylated RPA2, which coincided with a decreased recruitment of Rad51 to chromatin. Combined, these data suggest that the interaction between Cdh1 and CtIP is required to prevent excessive DNA-end resection in order to perform functional HR repair.
Reviewer, minor point: In general, Figure 7F could be better described in the figure legend and the fact that the WB is currently labeled siCdh1 was quite confusing. I presume this is a mistake and it should be labeled siCtIP instead.
We presume that the reviewer refers to Figure 5F . We have changed the description for Figure 7F , and have changed the labeling of the indicated Western blot, which was indeed mislabeled.
Reviewer, minor point: Page 21, 4 line from bottom: CtIP 'retrains' ExoI activity; Do the authors mean 'restrains'?
Response: The sentence was removed.
2nd Editorial Decision 25 September 2014
Thank you for submitting your revised manuscript for our consideration. It has now been seen once more by two of the original referees (see comments below), and I am happy to inform you that there are no further objections towards publication in The EMBO Journal.
Before we will able to send you a formal letter of acceptance, there are a few minor things I need to ask you for: -please send us (via email attachment) a modified text document incorporating the remaining minor suggestions of referee 2.
-please include in the email text a draft of 2-5 one-sentence 'bullet points' (complementary to the abstract) that summarize key aspects of the paper -they will form the basis for a 'synopsis' accompanying the online version of the article. Please see the latest research articles on our website (emboj.embopress.org) for examples.
After that, we should then be able to swiftly proceed with formal acceptance and production of the manuscript! ___________________________________ Referee #2
The manuscript is significantly improved after the revision. Authors have answered most of the questions raised by the reviewers. Two minor points need to be clarified or commented on.
1. Since CtIP KEN mutant exhibits sensitivity to PARP inhibitor but not to other damaging agents as Cdh1 deficient cells, it should be indicated in the abstract that APC/C-Cdh1 safeguards genome integrity at least in part through controlling CtIP stability in a cell cycle-and DNA damagedependent manner.
2. It is surprising that HR is only marginally decreased in the CtIP-T847A mutant ( figure 8D ), whereas a number of reports showed a significant reduction of HR and/or end resection in this mutant (Polato et al, J. Exp. Med. 211: 1027-36; Wang et al, Mol Cell 54:1012-21; Huertas et al, J Biol Chem. 284:9558-65) . In this study, authors also show strong sensitivity of this mutant to PARP inhibitor, which is often associated with HR defect. Please comment.
